

1 ENGROSSED HOUSE  
2 BILL NO. 1074

By: Morrissette, Echols,  
Hoskin, Nelson and Sherrer  
of the House

3  
4 and

Standridge of the Senate

5  
6  
7  
8 An Act relating to public health and safety; creating  
9 the Right to Try Act; defining terms; permitting  
10 certain manufacturer to make certain drugs available  
11 to eligible patient; permitting health insurance  
12 carrier to provide certain coverage; permitting  
13 insurer to deny certain coverage under certain  
14 conditions; prohibiting certain acts of licensing  
board of health care providers; prohibiting state  
officials from blocking eligible patients' access to  
certain drugs; providing certain act does not create  
private cause of action; providing for construction;  
providing for codification; and providing an  
effective date.

15  
16  
17 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

18 SECTION 1. NEW LAW A new section of law to be codified  
19 in the Oklahoma Statutes as Section 3091.1 of Title 63, unless there  
20 is created a duplication in numbering, reads as follows:

21 This act shall be known and may be cited as the "Right to Try  
22 Act".  
23  
24

1 SECTION 2. NEW LAW A new section of law to be codified  
2 in the Oklahoma Statutes as Section 3091.2 of Title 63, unless there  
3 is created a duplication in numbering, reads as follows:

4 For purposes of the Right to Try Act:

5 1. "Eligible patient" means a person who has:

- 6 a. a terminal illness, attested to by the patient's  
7 treating physician,
- 8 b. considered all other treatment options currently  
9 approved by the United States Food and Drug  
10 Administration,
- 11 c. been unable to participate in a clinical trial for the  
12 terminal illness within one hundred (100) miles of the  
13 patient's home address, or not been accepted to the  
14 clinical trial within one (1) week of completion of  
15 the clinical trial application process,
- 16 d. received a recommendation from his or her physician  
17 for the use of an investigational drug, biological  
18 product or device,
- 19 e. given written, informed consent for the use of the  
20 investigational drug, biological product or device or,  
21 if the patient is a minor or lacks the mental capacity  
22 to provide informed consent, a parent or legal  
23 guardian has given written, informed consent on the  
24 patient's behalf, and

1 f. documentation from his or her physician that he or she  
2 meets the requirements of this paragraph.

3 "Eligible patient" does not include a person being treated as an  
4 inpatient in a hospital licensed pursuant to the provisions of  
5 Section 1-701 et seq. of Title 63 of the Oklahoma Statutes;

6 2. "Investigational drug, biological product or device" means a  
7 drug, biological product or device that has successfully completed  
8 phase one of a clinical trial but has not yet been approved for  
9 general use by the United States Food and Drug Administration and  
10 remains under investigation in a clinical trial approved by the  
11 United States Food and Drug Administration;

12 3. "Terminal illness" means a disease that, without life-  
13 sustaining procedures, will soon result in death or a state of  
14 permanent unconsciousness from which recovery is unlikely; and

15 4. "Written, informed consent" means a written document signed  
16 by the patient and attested to by the patient's physician and a  
17 witness that, at a minimum:

18 a. explains the currently approved products and  
19 treatments for the disease or condition from which the  
20 patient suffers,

21 b. attests to the fact that the patient concurs with his  
22 or her physician in believing that all currently  
23 approved and conventionally recognized treatments are  
24 unlikely to prolong the patient's life,

- 1 c. clearly identifies the specific proposed  
2 investigational drug, biological product or device  
3 that the patient is seeking to use,  
4 d. describes the best and worst potential outcomes of  
5 using the investigational drug, biological product or  
6 device with a realistic description of the most likely  
7 outcome, including the possibility that new,  
8 unanticipated, different or worse symptoms might  
9 result, and that death could be hastened by the  
10 proposed treatment, based on the physician's knowledge  
11 of the proposed treatment in conjunction with an  
12 awareness of the patient's condition,  
13 e. makes clear that the patient's health insurer and  
14 provider are not obligated to pay for any care or  
15 treatments consequent to the use of the  
16 investigational drug, biological product or device,  
17 f. makes clear that the patient's eligibility for hospice  
18 care may be withdrawn if the patient begins curative  
19 treatment and care may be reinstated if the curative  
20 treatment ends and the patient meets hospice  
21 eligibility requirements,  
22 g. makes clear that in-home health care may be denied if  
23 treatment begins, and  
24

1           h.    states that the patient understands that he or she is  
2           liable for all expenses consequent to the use of the  
3           investigational drug, biological product or device,  
4           and that this liability extends to the patient's  
5           estate unless a contract between the patient and the  
6           manufacturer of the drug, biological product or device  
7           states otherwise.

8           SECTION 3.        NEW LAW        A new section of law to be codified  
9           in the Oklahoma Statutes as Section 3091.3 of Title 63, unless there  
10          is created a duplication in numbering, reads as follows:

11          A.    A manufacturer of an investigational drug, biological  
12          product or device may make available the manufacturer's  
13          investigational drug, biological product or device to eligible  
14          patients pursuant to the Right to Try Act.  An investigational drug,  
15          biological product or device may be made available through a  
16          pharmacy.  This act does not require that a manufacturer make  
17          available an investigational drug, biological product or device to  
18          an eligible patient.

19          B.    A manufacturer may:

20                1.    Provide an investigational drug, biological product or  
21                device to an eligible patient without receiving compensation; or

22                2.    Require an eligible patient to pay the costs of, or the  
23                costs associated with, the manufacture of the investigational drug,  
24                biological product or device.

1 C. A health insurance carrier may, but is not required to,  
2 provide coverage for the cost of an investigational drug, biological  
3 product or device.

4 D. An insurer may deny coverage to an eligible patient from the  
5 time the eligible patient begins use of the investigational drug,  
6 biological product or device through a period not to exceed six (6)  
7 months from the time the investigational drug, biological product or  
8 device is no longer used by the eligible patient; provided, that  
9 coverage may not be denied for a preexisting condition and for  
10 coverage for benefits which commenced prior to the time the eligible  
11 patient begins use of such drug, biological product or device.

12 E. If a patient dies while being treated by an investigational  
13 drug, biological product or device, the patient's heirs are not  
14 liable for any outstanding debt related to the treatment or lack of  
15 insurance due to the treatment.

16 SECTION 4. NEW LAW A new section of law to be codified  
17 in the Oklahoma Statutes as Section 3091.4 of Title 63, unless there  
18 is created a duplication in numbering, reads as follows:

19 Notwithstanding any other law, a licensing board may not revoke,  
20 fail to renew, suspend or take any action against a health care  
21 provider's license, based solely on the health care provider's  
22 recommendations to an eligible patient regarding access to or  
23 treatment with an investigational drug, biological product or  
24 device, as long as the recommendations are consistent with medical

1 standards of care. Action against a health care provider's Medicare  
2 certification based solely on the health care provider's  
3 recommendation that a patient have access to an investigational  
4 drug, biological product or device is prohibited.

5 SECTION 5. NEW LAW A new section of law to be codified  
6 in the Oklahoma Statutes as Section 3091.5 of Title 63, unless there  
7 is created a duplication in numbering, reads as follows:

8 An official, employee or agent of this state shall not block or  
9 attempt to block an eligible patient's access to an investigational  
10 drug, biological product or device. Counseling, advice or a  
11 recommendation consistent with medical standards of care from a  
12 licensed health care provider is not a violation of this section.

13 SECTION 6. NEW LAW A new section of law to be codified  
14 in the Oklahoma Statutes as Section 3091.6 of Title 63, unless there  
15 is created a duplication in numbering, reads as follows:

16 The Right to Try Act does not create a private cause of action  
17 against a manufacturer of an investigational drug, biological  
18 product or device or against another person or entity involved in  
19 the care of an eligible patient using the investigational drug,  
20 biological product or device, for any harm done to the eligible  
21 patient resulting from the investigational drug, biological product  
22 or device, so long as the manufacturer or other person or entity is  
23 complying in good faith with the terms of the Right to Try Act,  
24 unless there was a failure to exercise reasonable care.

1 SECTION 7. NEW LAW A new section of law to be codified  
2 in the Oklahoma Statutes as Section 3091.7 of Title 63, unless there  
3 is created a duplication in numbering, reads as follows:

4 Nothing in the Right to Try Act affects the mandatory health  
5 care coverage for participation in clinical trials.

6 SECTION 8. This act shall become effective November 1, 2015.

7 Passed the House of Representatives the 3rd day of March, 2015.

8

9

\_\_\_\_\_  
Presiding Officer of the House  
of Representatives

10

11

Passed the Senate the \_\_\_\_ day of \_\_\_\_\_, 2015.

12

13

14

\_\_\_\_\_  
Presiding Officer of the Senate

15

16

17

18

19

20

21

22

23

24